
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics is well positioned to capitalize on the potential of precision therapeutics, with their proprietary platform providing a deeper understanding of gene expression and potential drug targets. The company has a diverse pipeline, with FHD-909 in Phase 1 trials, and promising preclinical data for their combination treatments for AML. Leadership with strong experience and partnerships with experts in oncology further solidify the potential success of Foghorn's approach.
Bears say
Foghorn Therapeutics is a clinical stage biotechnology company that focuses on developing precision therapeutics for serious diseases through targeting the chromatin regulatory system. While they have a promising flagship program, FHD-909, there are significant development and competitive risks facing the company. Additionally, their partner, Eli Lilly, will play a crucial role in the success of FHD-909 and until data is disclosed, it is unclear if the partnership will move forward. Furthermore, their reliance on their proprietary platform and the need for high target coverage for optimal efficacy may pose challenges for future development.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares